Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Friday, 1 September 2017

Shire plc : Total voting rights

Shire plc    

Published: 12:30 CEST 01-09-2017 /GlobeNewswire /Source: Shire plc / : SHP /ISIN: JE00B2QKY057

Shire plc : Total voting rights

 

 

 


Total Voting Rights

 

September 1, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority's (the "FCA") Disclosure Guidance and Transparency Rules, notifies the market of the following:

 

As at August 31, 2017, the Company's issued ordinary share capital comprised 908,286,588 ordinary shares of 5 pence each with voting rights and a further 7,357,283 ordinary shares held in treasury.

 

Therefore, the total number of voting rights in the Company is 908,286,588. This is the figure which should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

Sarah Rixon

Company Secretarial Assistant

 

 

For further information please contact:

 

Investor Relations

 

 

Ian Karp

ikarp@shire.com

+1 781 482 9018

Robert Coates

rcoates@shire.com

+44 1256 894874

Media

 

 

Lisa Adler

lisa.adler@shire.com

+1 617 588 8607

Debbi Ford

debbi.ford@shire.com 

+1 617 949 9083

 

 

NOTES TO EDITORS

 

About Shire

 

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

 

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

 

www.shire.com





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Shire plc, 1 Kingdom Street Paddington, London W2 6BD, United Kingdom
If you would like to unsubscribe and stop receiving these e-mails click here.